immunoSEQ T-MAP COVID

immunoSEQ T-MAP COVID

Platform Technology

Information

Adaptive Biotechnologies' unique MIRA Technology and immunoSEQ Technology has enabled us to create a comprehensive view of the T-cell response to SARS-CoV-2 infection. This data has been made public as part of the ImmuneCODE Initiative in order to help propel drug, vaccine, and clinical trial research. We are launching immunoSEQ T-MAP COVID with the tools to study and analyze the COVID-19 T-cell immune response map. Research Use Only. Not for use in diagnostic procedures.
Adaptive BiotechnologiesAdaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have two commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. 

Join the event!